^
    1d
    Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review. (PubMed, Intern Med)
    The efficacy of TKIs was consistent across SQC forms (including de novo or adenocarcinoma-transformed cases) and EGFR mutation types. The findings indicate that, compared with early-generation TKIs, third-generation TKIs are effective against de novo SQCs and should be considered a plausible treatment option for transformed SQCs.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    2d
    TATTON: AZD9291 in Combination With Ascending Doses of Novel Therapeutics (clinicaltrials.gov)
    P1, N=344, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    2d
    Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Chinese University of Hong Kong
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    2d
    FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Recruiting, Axcynsis Therapeutics Pte Ltd | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • CLDN6 (Claudin 6)
    |
    EGFR mutation
    2d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. (clinicaltrials.gov)
    P2, N=36, Recruiting, Guangzhou Medical University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Mar 2027
    Enrollment open • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • pemetrexed • simmitinib (SYHA1817)
    2d
    Changes in EGFR activity following CRISPR/Cas9-editing of the EGF binding domain. (PubMed, Sci Rep)
    Disruption of ligand binding domain of EGFR by sequential knock in CRISPR/Cas9 genome editing altered subcellular localization and phosphorylation of EGFR in cervical cancer cells. The results presented here provide insights that may accelerate the development of CRISPR/Cas9-based therapies for EGFR-dependent cancers and reinforce the importance of thorough evaluation of CRISPR/Cas9-generated phenotypes.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    3d
    First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient? (PubMed, Drugs)
    For classical EGFR mutations such as exon 19 deletion and exon 21 L858R mutation, combination strategies in the first-line setting, based on the results of the MARIPOSA (lazertinib and amivantamab) and FLAURA 2 (platinum-based doublet chemotherapy and osimertinib) trials, provide promising outcomes. Optimising the treatment sequence in advanced EGFR-mutated NSCLC is crucial to ensure the best survival outcomes along with the best treatment tolerance and quality of life. Predictive biomarkers are strongly needed as well as biomarker-based escalation and de-escalation clinical trials.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Lazcluze (lazertinib) • simmitinib (SYHA1817)
    3d
    Study on the resistance mechanism of ANGPTL4 mediated by NF-Kb/HIF-1 α to osimertinib in non-small cell lung cancer (ChiCTR2600117670)
    P=N/A, N=8, Not yet recruiting, Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital); Guangdong Second Provincial General Hospital (Guangdong Provin
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    A study evaluating the efficacy and safety of aumolertinib mesylate as first-line therapy in patients with EGFR-mutated stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD) (ChiCTR2600117077)
    P=N/A, N=51, Not yet recruiting, Tianjin Chest Hospital; Tianjin Chest Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Ameile (aumolertinib)
    3d
    A Prospective Multicenter Study of Stereotactic Ablative Radiotherapy Combined with Immunotherapy for Early-Stage Non-Small Cell Lung Cancer (ChiCTR2600116150)
    P=N/A, N=35, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    3d
    Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC with Leptomeningeal Metastasis (ChiCTR2600116031)
    P=N/A, N=42, Not yet recruiting, Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Ivesa (firmonertinib)
    3d
    Exploration of the Efficacy and Safety of metronomic chemotherapy with vinorelbine capsules combined with third-generation EGFR-TKI as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations (ChiCTR2500115674)
    P=N/A, N=66, Not yet recruiting, Beijing hospital; Beijing hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Ameile (aumolertinib) • vinorelbine tartrate • Ivesa (firmonertinib) • simmitinib (SYHA1817)